A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.